| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 32 | 2021 | 480 | 3.230 |
Why?
|
| Heart Defects, Congenital | 29 | 2023 | 1795 | 2.780 |
Why?
|
| Critical Care | 17 | 2023 | 799 | 2.570 |
Why?
|
| Cardiopulmonary Bypass | 14 | 2021 | 391 | 2.290 |
Why?
|
| Shock, Septic | 20 | 2018 | 188 | 2.080 |
Why?
|
| Heart Diseases | 12 | 2019 | 724 | 1.800 |
Why?
|
| Cardiac Surgical Procedures | 17 | 2024 | 1159 | 1.690 |
Why?
|
| Respiratory Syncytial Virus Infections | 9 | 2019 | 444 | 1.320 |
Why?
|
| Infant | 70 | 2023 | 14006 | 1.240 |
Why?
|
| Critical Illness | 10 | 2022 | 740 | 1.240 |
Why?
|
| Heart Arrest | 7 | 2019 | 382 | 1.220 |
Why?
|
| Diuretics | 3 | 2017 | 171 | 1.210 |
Why?
|
| Clinical Deterioration | 2 | 2017 | 12 | 1.170 |
Why?
|
| Multiple Organ Failure | 6 | 2022 | 177 | 1.150 |
Why?
|
| Diuresis | 2 | 2017 | 63 | 1.140 |
Why?
|
| Hospital Rapid Response Team | 2 | 2017 | 38 | 1.110 |
Why?
|
| Hospitals, Pediatric | 8 | 2023 | 799 | 1.090 |
Why?
|
| Troponin I | 6 | 2006 | 130 | 1.040 |
Why?
|
| Morbidity | 5 | 2016 | 400 | 1.040 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2019 | 347 | 0.990 |
Why?
|
| Consensus | 5 | 2017 | 1106 | 0.920 |
Why?
|
| Oxygen | 4 | 2012 | 792 | 0.900 |
Why?
|
| Hemodynamics | 8 | 2022 | 950 | 0.900 |
Why?
|
| Child | 72 | 2023 | 30578 | 0.840 |
Why?
|
| Hypoplastic Left Heart Syndrome | 5 | 2021 | 253 | 0.830 |
Why?
|
| Child, Preschool | 55 | 2020 | 17068 | 0.790 |
Why?
|
| Length of Stay | 10 | 2019 | 2008 | 0.780 |
Why?
|
| Infant, Newborn | 33 | 2023 | 8701 | 0.770 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2018 | 641 | 0.760 |
Why?
|
| Coronary Care Units | 2 | 2018 | 38 | 0.750 |
Why?
|
| Nitric Oxide | 3 | 2014 | 659 | 0.710 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2017 | 327 | 0.710 |
Why?
|
| Respiratory Syncytial Viruses | 4 | 2017 | 172 | 0.710 |
Why?
|
| Shock | 2 | 2013 | 93 | 0.700 |
Why?
|
| Monitoring, Physiologic | 7 | 2022 | 522 | 0.700 |
Why?
|
| Heart Failure | 8 | 2020 | 2333 | 0.680 |
Why?
|
| Postoperative Complications | 10 | 2020 | 5682 | 0.660 |
Why?
|
| Intensive Care Units | 6 | 2023 | 738 | 0.660 |
Why?
|
| Heart-Assist Devices | 5 | 2019 | 1045 | 0.640 |
Why?
|
| Acute Kidney Injury | 6 | 2017 | 761 | 0.640 |
Why?
|
| Epinephrine | 3 | 2018 | 240 | 0.630 |
Why?
|
| Vasodilator Agents | 3 | 2018 | 230 | 0.620 |
Why?
|
| Humans | 129 | 2024 | 271010 | 0.610 |
Why?
|
| Metolazone | 1 | 2017 | 5 | 0.600 |
Why?
|
| Syringes | 1 | 2017 | 40 | 0.590 |
Why?
|
| Evidence-Based Medicine | 4 | 2022 | 1035 | 0.580 |
Why?
|
| Pediatrics | 9 | 2021 | 1189 | 0.580 |
Why?
|
| Spironolactone | 1 | 2017 | 23 | 0.580 |
Why?
|
| Potassium | 2 | 2022 | 340 | 0.570 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.560 |
Why?
|
| Nephrons | 1 | 2016 | 42 | 0.560 |
Why?
|
| Cardiac Output | 4 | 2022 | 194 | 0.550 |
Why?
|
| Sepsis | 6 | 2017 | 686 | 0.540 |
Why?
|
| Truth Disclosure | 1 | 2018 | 179 | 0.540 |
Why?
|
| Emergency Treatment | 1 | 2017 | 104 | 0.540 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 15 | 0.520 |
Why?
|
| Alprostadil | 1 | 2015 | 37 | 0.510 |
Why?
|
| Respiration, Artificial | 10 | 2019 | 587 | 0.510 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2016 | 50 | 0.500 |
Why?
|
| Heart Rate | 2 | 2017 | 752 | 0.500 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2020 | 565 | 0.480 |
Why?
|
| Troponin | 2 | 2012 | 87 | 0.480 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 4379 | 0.480 |
Why?
|
| Weight Gain | 1 | 2017 | 472 | 0.470 |
Why?
|
| Postoperative Care | 6 | 2019 | 730 | 0.470 |
Why?
|
| Premedication | 2 | 2005 | 133 | 0.470 |
Why?
|
| Tetralogy of Fallot | 2 | 2012 | 164 | 0.460 |
Why?
|
| Hypotension | 3 | 2021 | 232 | 0.460 |
Why?
|
| Water | 1 | 2016 | 389 | 0.450 |
Why?
|
| Blood Pressure | 3 | 2019 | 1571 | 0.450 |
Why?
|
| Pain, Postoperative | 2 | 2024 | 663 | 0.450 |
Why?
|
| Biomarkers | 20 | 2018 | 5063 | 0.450 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2014 | 317 | 0.440 |
Why?
|
| Antiviral Agents | 5 | 2019 | 1253 | 0.440 |
Why?
|
| Male | 68 | 2022 | 128533 | 0.440 |
Why?
|
| Furosemide | 3 | 2017 | 40 | 0.430 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2013 | 49 | 0.430 |
Why?
|
| Ventricular Fibrillation | 2 | 2003 | 59 | 0.430 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2014 | 625 | 0.400 |
Why?
|
| Palivizumab | 6 | 2019 | 62 | 0.400 |
Why?
|
| Female | 68 | 2022 | 149107 | 0.400 |
Why?
|
| Heart Transplantation | 4 | 2010 | 897 | 0.390 |
Why?
|
| Norwood Procedures | 2 | 2023 | 101 | 0.380 |
Why?
|
| Vascular Resistance | 1 | 2012 | 213 | 0.380 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2024 | 451 | 0.380 |
Why?
|
| Heart Injuries | 1 | 2011 | 51 | 0.380 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2012 | 183 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 464 | 0.370 |
Why?
|
| Down Syndrome | 1 | 2013 | 227 | 0.370 |
Why?
|
| Retrospective Studies | 27 | 2023 | 39902 | 0.350 |
Why?
|
| Linear Models | 3 | 2017 | 1098 | 0.340 |
Why?
|
| Postoperative Period | 5 | 2017 | 667 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 3 | 2008 | 596 | 0.330 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 2224 | 0.330 |
Why?
|
| Risk Factors | 17 | 2020 | 17904 | 0.320 |
Why?
|
| Hospitalization | 4 | 2019 | 2171 | 0.320 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2009 | 46 | 0.320 |
Why?
|
| Dexamethasone | 2 | 2005 | 1517 | 0.320 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2001 | 76 | 0.310 |
Why?
|
| Matrix Metalloproteinase 8 | 6 | 2017 | 16 | 0.300 |
Why?
|
| Vasodilation | 1 | 2009 | 216 | 0.300 |
Why?
|
| Acetaminophen | 2 | 2019 | 125 | 0.300 |
Why?
|
| Glucocorticoids | 3 | 2015 | 618 | 0.300 |
Why?
|
| Societies, Medical | 6 | 2023 | 1321 | 0.300 |
Why?
|
| Databases, Factual | 3 | 2008 | 2251 | 0.290 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 255 | 0.290 |
Why?
|
| Steroids | 1 | 2009 | 372 | 0.280 |
Why?
|
| Prospective Studies | 18 | 2021 | 13424 | 0.280 |
Why?
|
| Hydrocortisone | 3 | 2018 | 404 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 1469 | 0.270 |
Why?
|
| Risk Assessment | 12 | 2020 | 6772 | 0.270 |
Why?
|
| Near Drowning | 1 | 2006 | 26 | 0.260 |
Why?
|
| Biological Transport | 3 | 2011 | 627 | 0.260 |
Why?
|
| Obesity | 1 | 2017 | 2905 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 3409 | 0.250 |
Why?
|
| Organ Dysfunction Scores | 2 | 2022 | 69 | 0.250 |
Why?
|
| Carbon Dioxide | 2 | 2023 | 328 | 0.240 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2017 | 163 | 0.240 |
Why?
|
| Granzymes | 4 | 2017 | 94 | 0.240 |
Why?
|
| Methylprednisolone | 1 | 2005 | 198 | 0.240 |
Why?
|
| Natriuretic Agents | 3 | 2017 | 32 | 0.240 |
Why?
|
| Treatment Outcome | 20 | 2024 | 33774 | 0.240 |
Why?
|
| Texas | 7 | 2017 | 6450 | 0.230 |
Why?
|
| Transcriptome | 4 | 2021 | 1962 | 0.230 |
Why?
|
| Cardiotonic Agents | 2 | 2017 | 156 | 0.230 |
Why?
|
| Respiratory Insufficiency | 2 | 2007 | 345 | 0.230 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 2346 | 0.230 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2019 | 223 | 0.230 |
Why?
|
| Positive-Pressure Respiration | 1 | 2004 | 123 | 0.230 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 244 | 0.220 |
Why?
|
| Age Factors | 10 | 2020 | 5468 | 0.220 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2003 | 26 | 0.220 |
Why?
|
| Ventricular Dysfunction | 1 | 2003 | 33 | 0.220 |
Why?
|
| Models, Theoretical | 4 | 2015 | 800 | 0.220 |
Why?
|
| Peer Review | 1 | 2023 | 82 | 0.210 |
Why?
|
| Neonatology | 1 | 2023 | 50 | 0.210 |
Why?
|
| Hemodynamic Monitoring | 1 | 2022 | 12 | 0.210 |
Why?
|
| Myocardium | 1 | 2008 | 1233 | 0.210 |
Why?
|
| Chemokine CCL3 | 3 | 2017 | 65 | 0.210 |
Why?
|
| Interleukin-8 | 4 | 2017 | 531 | 0.210 |
Why?
|
| United States | 15 | 2023 | 15868 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 4329 | 0.200 |
Why?
|
| Intubation, Intratracheal | 2 | 2023 | 469 | 0.200 |
Why?
|
| Clinical Protocols | 1 | 2004 | 478 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2018 | 632 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 5071 | 0.200 |
Why?
|
| Tissue Donors | 1 | 2006 | 821 | 0.200 |
Why?
|
| Intracranial Hypertension | 1 | 2003 | 126 | 0.190 |
Why?
|
| Dietary Supplements | 2 | 2018 | 563 | 0.190 |
Why?
|
| Mentoring | 1 | 2023 | 105 | 0.190 |
Why?
|
| Airway Obstruction | 1 | 2004 | 273 | 0.190 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2003 | 160 | 0.190 |
Why?
|
| Emergency Medical Services | 1 | 2006 | 470 | 0.190 |
Why?
|
| Infant, Premature | 3 | 2019 | 844 | 0.180 |
Why?
|
| Palliative Care | 3 | 2014 | 2178 | 0.180 |
Why?
|
| Time Factors | 10 | 2022 | 13024 | 0.180 |
Why?
|
| California | 3 | 2006 | 212 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 256 | 0.170 |
Why?
|
| Oximetry | 3 | 2021 | 190 | 0.170 |
Why?
|
| Ketamine | 1 | 2023 | 241 | 0.170 |
Why?
|
| Myocardial Contraction | 2 | 2017 | 301 | 0.170 |
Why?
|
| Triiodothyronine | 1 | 2019 | 84 | 0.160 |
Why?
|
| Models, Statistical | 2 | 2016 | 1185 | 0.160 |
Why?
|
| Double-Blind Method | 3 | 2018 | 2590 | 0.160 |
Why?
|
| Perioperative Care | 3 | 2023 | 447 | 0.150 |
Why?
|
| Metabolome | 1 | 2021 | 355 | 0.150 |
Why?
|
| Thyroxine | 1 | 2018 | 115 | 0.150 |
Why?
|
| Adolescent | 14 | 2023 | 32777 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 552 | 0.150 |
Why?
|
| Odds Ratio | 3 | 2019 | 2311 | 0.150 |
Why?
|
| Quality of Life | 1 | 2012 | 4778 | 0.150 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 131 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2016 | 1208 | 0.150 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 5151 | 0.150 |
Why?
|
| Acetazolamide | 1 | 2017 | 35 | 0.150 |
Why?
|
| Airway Extubation | 2 | 2023 | 74 | 0.150 |
Why?
|
| Chlorides | 1 | 2018 | 129 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2017 | 74 | 0.150 |
Why?
|
| Hospital Mortality | 5 | 2020 | 1235 | 0.140 |
Why?
|
| Biofilms | 1 | 2019 | 205 | 0.140 |
Why?
|
| Coronary Aneurysm | 1 | 1997 | 35 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2019 | 207 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 15231 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 192 | 0.140 |
Why?
|
| Hypokalemia | 1 | 2017 | 61 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 214 | 0.140 |
Why?
|
| Prognosis | 9 | 2018 | 22509 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 98 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 258 | 0.140 |
Why?
|
| Data Collection | 1 | 2019 | 608 | 0.140 |
Why?
|
| Logistic Models | 5 | 2017 | 3448 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2017 | 314 | 0.130 |
Why?
|
| Patient Selection | 1 | 2004 | 2026 | 0.130 |
Why?
|
| Asthma | 1 | 2004 | 895 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 363 | 0.130 |
Why?
|
| Birthing Centers | 1 | 2015 | 10 | 0.130 |
Why?
|
| ROC Curve | 3 | 2017 | 1250 | 0.130 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 208 | 0.130 |
Why?
|
| Hyperkalemia | 1 | 2017 | 79 | 0.130 |
Why?
|
| Ventilators, Mechanical | 1 | 2016 | 47 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 591 | 0.130 |
Why?
|
| Case-Control Studies | 8 | 2018 | 6239 | 0.130 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 163 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 256 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 170 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2003 | 882 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 380 | 0.130 |
Why?
|
| Acute Disease | 5 | 2018 | 2496 | 0.120 |
Why?
|
| Body Fluids | 1 | 2016 | 121 | 0.120 |
Why?
|
| Health Personnel | 2 | 2023 | 653 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2017 | 9479 | 0.120 |
Why?
|
| Patient Admission | 2 | 2014 | 231 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1181 | 0.120 |
Why?
|
| Resuscitation | 1 | 2017 | 274 | 0.120 |
Why?
|
| Tertiary Care Centers | 2 | 2014 | 417 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 263 | 0.120 |
Why?
|
| Administration, Inhalation | 2 | 2014 | 300 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 244 | 0.120 |
Why?
|
| Bacteria | 1 | 2019 | 654 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 626 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2022 | 701 | 0.120 |
Why?
|
| Patient Readmission | 2 | 2020 | 572 | 0.110 |
Why?
|
| Bradycardia | 1 | 2014 | 73 | 0.110 |
Why?
|
| Water-Electrolyte Balance | 1 | 2014 | 97 | 0.110 |
Why?
|
| Cardiology | 3 | 2016 | 511 | 0.110 |
Why?
|
| Coronary Disease | 1 | 1997 | 767 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 1302 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 256 | 0.110 |
Why?
|
| gamma-Linolenic Acid | 1 | 2013 | 3 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 4965 | 0.110 |
Why?
|
| Missouri | 1 | 2012 | 41 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 2013 | 188 | 0.110 |
Why?
|
| Gases | 1 | 2012 | 39 | 0.110 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 54 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 151 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 564 | 0.100 |
Why?
|
| Drug Overdose | 1 | 2013 | 97 | 0.100 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2012 | 4 | 0.100 |
Why?
|
| Inflammation | 2 | 2020 | 2518 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2014 | 220 | 0.100 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 6195 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2012 | 2849 | 0.100 |
Why?
|
| Vancomycin | 1 | 2014 | 292 | 0.100 |
Why?
|
| Kidney | 2 | 2017 | 2122 | 0.100 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 92 | 0.100 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 95 | 0.100 |
Why?
|
| Endocrine System Diseases | 2 | 2010 | 89 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 285 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2016 | 591 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 986 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 4481 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2011 | 419 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 1558 | 0.100 |
Why?
|
| Heart | 1 | 2017 | 1195 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2014 | 2092 | 0.090 |
Why?
|
| Patient Care Team | 2 | 2006 | 823 | 0.090 |
Why?
|
| Cytokines | 2 | 2010 | 2826 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 130 | 0.090 |
Why?
|
| Interleukins | 1 | 2012 | 341 | 0.090 |
Why?
|
| Enteral Nutrition | 1 | 2013 | 347 | 0.090 |
Why?
|
| Drug Utilization Review | 2 | 2013 | 37 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 90 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2017 | 2238 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2014 | 1610 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 2401 | 0.090 |
Why?
|
| Adult | 6 | 2023 | 82090 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 522 | 0.080 |
Why?
|
| Gene Expression | 4 | 2012 | 3643 | 0.080 |
Why?
|
| Cross Infection | 2 | 2011 | 550 | 0.080 |
Why?
|
| Reperfusion | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2014 | 1712 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 2474 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 4134 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 1313 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 5171 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2005 | 67 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2017 | 6398 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 714 | 0.080 |
Why?
|
| RNA | 2 | 2010 | 1064 | 0.080 |
Why?
|
| Appendicitis | 1 | 2010 | 177 | 0.080 |
Why?
|
| Recovery of Function | 2 | 2019 | 684 | 0.080 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 563 | 0.070 |
Why?
|
| Mitochondria | 1 | 2014 | 1299 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2014 | 9294 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 1301 | 0.070 |
Why?
|
| Child Health Services | 1 | 2007 | 89 | 0.070 |
Why?
|
| Pregnancy | 2 | 2017 | 8131 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2351 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 9040 | 0.070 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2006 | 66 | 0.060 |
Why?
|
| Blood Group Antigens | 1 | 2006 | 76 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 5829 | 0.060 |
Why?
|
| Survival Rate | 3 | 2019 | 12542 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2003 | 1933 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2007 | 206 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 3187 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2006 | 128 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 408 | 0.060 |
Why?
|
| Genome, Human | 2 | 2014 | 1888 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2006 | 749 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 1437 | 0.060 |
Why?
|
| Prazosin | 1 | 2003 | 23 | 0.060 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 14 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2024 | 43 | 0.060 |
Why?
|
| Birth Weight | 1 | 2006 | 355 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2018 | 506 | 0.060 |
Why?
|
| Vasopressins | 1 | 2003 | 63 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2005 | 418 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2003 | 73 | 0.060 |
Why?
|
| Laryngeal Masks | 1 | 2004 | 78 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2010 | 1567 | 0.060 |
Why?
|
| Creatinine | 2 | 2017 | 529 | 0.060 |
Why?
|
| Heart Massage | 1 | 2003 | 30 | 0.060 |
Why?
|
| Defibrillators, Implantable | 2 | 2004 | 226 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2003 | 72 | 0.050 |
Why?
|
| Reoperation | 2 | 2018 | 1392 | 0.050 |
Why?
|
| Propranolol | 1 | 2003 | 158 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1551 | 0.050 |
Why?
|
| Tidal Volume | 1 | 2003 | 58 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2003 | 166 | 0.050 |
Why?
|
| Peer Review, Research | 1 | 2023 | 66 | 0.050 |
Why?
|
| Premature Birth | 1 | 2007 | 408 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 454 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2003 | 60 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2006 | 564 | 0.050 |
Why?
|
| Peer Group | 1 | 2023 | 141 | 0.050 |
Why?
|
| Calcium Chloride | 1 | 2021 | 25 | 0.050 |
Why?
|
| Aorta | 1 | 2006 | 670 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2023 | 215 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 2655 | 0.050 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 361 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 22260 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 2394 | 0.050 |
Why?
|
| Mentors | 1 | 2023 | 210 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 323 | 0.050 |
Why?
|
| Genomics | 2 | 2010 | 2837 | 0.050 |
Why?
|
| Myocardial Stunning | 1 | 2000 | 20 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2003 | 544 | 0.040 |
Why?
|
| Myofibrils | 1 | 2000 | 31 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 306 | 0.040 |
Why?
|
| Endocardium | 1 | 2000 | 51 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2022 | 142 | 0.040 |
Why?
|
| Methadone | 1 | 2022 | 214 | 0.040 |
Why?
|
| Morphine | 1 | 2022 | 333 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3846 | 0.040 |
Why?
|
| Skin Temperature | 1 | 2019 | 34 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 1062 | 0.040 |
Why?
|
| North America | 1 | 2020 | 338 | 0.040 |
Why?
|
| Swine | 1 | 2003 | 1607 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 4213 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2320 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 248 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 100 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 2364 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 853 | 0.040 |
Why?
|
| Leukocytes | 2 | 2011 | 422 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 139 | 0.040 |
Why?
|
| Oliguria | 1 | 2017 | 20 | 0.040 |
Why?
|
| Animals | 4 | 2024 | 62063 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2003 | 1155 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2016 | 38 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 286 | 0.030 |
Why?
|
| Adenosine | 1 | 2018 | 296 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 277 | 0.030 |
Why?
|
| Community Participation | 1 | 2016 | 54 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 492 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 399 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 2015 | 23 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2015 | 65 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2018 | 493 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 181 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 756 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 199 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 173 | 0.030 |
Why?
|
| Signal Transduction | 4 | 2015 | 12108 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2014 | 41 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 275 | 0.030 |
Why?
|
| Medicine | 1 | 2016 | 136 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 1075 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 729 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 417 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2185 | 0.030 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2013 | 45 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 441 | 0.030 |
Why?
|
| Food, Formulated | 1 | 2013 | 55 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1612 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 120 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 735 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 757 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 1174 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2211 | 0.020 |
Why?
|
| Calcitonin | 1 | 2012 | 182 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2012 | 168 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 347 | 0.020 |
Why?
|
| Family | 1 | 2016 | 784 | 0.020 |
Why?
|
| Aged | 1 | 2017 | 73460 | 0.020 |
Why?
|
| Leukocyte Elastase | 1 | 2011 | 71 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 397 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1940 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 870 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2012 | 249 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2013 | 255 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2016 | 699 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3531 | 0.020 |
Why?
|
| Child Mortality | 1 | 2010 | 22 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2010 | 75 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 680 | 0.020 |
Why?
|
| Health | 1 | 2010 | 51 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 286 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 7389 | 0.020 |
Why?
|
| Publications | 1 | 2010 | 54 | 0.020 |
Why?
|
| Heart Block | 1 | 2010 | 45 | 0.020 |
Why?
|
| Nutrition Therapy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Energy Intake | 1 | 2013 | 523 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 433 | 0.020 |
Why?
|
| Chylothorax | 1 | 2010 | 43 | 0.020 |
Why?
|
| Technology | 1 | 2010 | 101 | 0.020 |
Why?
|
| Research Report | 1 | 2010 | 136 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 111 | 0.020 |
Why?
|
| Blood Cells | 1 | 2009 | 129 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 503 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 4255 | 0.020 |
Why?
|
| Parents | 1 | 2016 | 1084 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 484 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 1311 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 233 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 5102 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4502 | 0.020 |
Why?
|
| Pregnancy, High-Risk | 1 | 2007 | 51 | 0.020 |
Why?
|
| Mice | 1 | 2008 | 35608 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2007 | 39 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 483 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1076 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2005 | 119 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 187 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 608 | 0.020 |
Why?
|
| Elapid Venoms | 1 | 2004 | 11 | 0.020 |
Why?
|
| Infant Welfare | 1 | 2004 | 28 | 0.010 |
Why?
|
| Ultrafiltration | 1 | 2004 | 25 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2008 | 757 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2010 | 694 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 1164 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6517 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 453 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 2423 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 659 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 4832 | 0.010 |
Why?
|
| Sarcomeres | 1 | 2000 | 34 | 0.010 |
Why?
|
| Crystallins | 1 | 2000 | 30 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2000 | 95 | 0.010 |
Why?
|
| Myosins | 1 | 2000 | 97 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2000 | 107 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 206 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 438 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 1830 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 708 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 7045 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 1504 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2000 | 330 | 0.010 |
Why?
|
| Dogs | 1 | 2000 | 1160 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 3900 | 0.010 |
Why?
|
| Neoplasms | 1 | 2017 | 15933 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 7758 | 0.000 |
Why?
|